Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1193

Milatuzumab

Home » Antibodies » Milatuzumab

Background of Milatuzumab

Milatuzumab, also known as hLL1 or IMMU-115, is a humanized monoclonal antibody that targets a specific epitope of the CD74 molecule expressed on monocytes, macrophages, and B cells. Currently, Milatuzumab is being investigated as an immunotherapeutic candidate for the treatment of multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL).

Specifications

Catalog Number:
KB-1193
Antibody Name:
Milatuzumab
Isotype:
Human IgG1,kappa
FC Muations:
Wild Type
Target:
CD74
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ: Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology. 1999, 98: 296-302. 10.1046/j.1365-2567.1999.00868.x.
  2. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM: CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007, 13: 5556s-5563s. 10.1158/1078-0432.CCR-07-1167.